Form 8-K - Current report:
SEC Accession No. 0000950170-25-057323
Filing Date
2025-04-23
Accepted
2025-04-23 16:01:15
Documents
12
Period of Report
2025-04-18
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vktx-20250418.htm   iXBRL 8-K 51538
2 EX-16.1 vktx-ex16_1.htm EX-16.1 4956
  Complete submission text file 0000950170-25-057323.txt   170747

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20250418.xsd EX-101.SCH 25033
14 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20250418_htm.xml XML 4545
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37355 | Film No.: 25861333
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)